Navigation Links
Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Date:5/1/2008

-- Presentations highlight Palomid 529 as an inhibitor of macular

degeneration, diabetic retinopathy and retinal scaring from retinal

detachment in animal disease models ---

JAMAICA PLAIN, Mass., May 1 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced it has presented two presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) describing the activity of Palomid 529 in a series of models of retinal disease notably macular degeneration, diabetic retinopathy and retinal fibrosis.

P529 is a non-steroidal, synthetic, small molecule drug created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work. Palomid's broad activity as an anti-angiogenic and anti-proliferative agent is shown to reside in its ability to target and inhibit the PI3K/Akt/mTOR signal transduction pathway as a TORC1/TORC2 inhibitor.

The first of the two presentations, "Palomid 529, a Non-Steroidal Small Molecule Anti-Angiogenic Agent Inhibits Retinal and Subretinal Neovascularization by Inhibiting the PI3K/Akt/mTOR Pathway", was given as an oral presentation by Dr. David Sherris, President and CEO of Paloma Pharmaceuticals. The second presentation, "Muller Cell Proliferation and Glial Scar Formation Is Reduced Following Experimental Retinal Detachment Using Palomid 529, an Inhibitor of the Akt/mTOR Pathway", was given by the Drs. Geoffrey P. Lewis and Steven. K. Fisher, presented by Dr. Ethan A. Chapin, of the Neuroscience Research Institute, Neuroscience Research Institute, MCD Biology, University of California-Santa Barbara, Santa Barbara, CA.

"Ocular diseases of both retinal and sub-retinal origin, namely diabetic retinopathy and age-related macular degeneration, are a significant problem in our aging population. In order to create a drug to optimally treat such diseases one needs to prevent or inhibit disease pr
'/>"/>

SOURCE Paloma Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
2. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
5. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
7. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
8. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
10. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
11. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products ... lead the expansion of global cosmeceutical and skin care brands. Mr. Fernandez ... the last 25 years working in operations, purchasing and management for some of ...
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College President Chris Bustamante ... Vice President of Strategic Initiatives and Information Services. O’Shea, who has served Rio Salado ... its reach and impact through innovative technologies and strategies. , “I am very proud ...
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor Day weekend, the last ... on September 22nd this year). For IT security personnel, it should also mark the ... prove far more costly than a simple headache. , Joe Caruso, founder and CEO-CTO ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... Exhibiting people evidence of the harm unhealthy habits do can ... of studies on biomarkers indicators of health or disease ... people's behaviour. ,They learned that if you reveal ... smoking it does encourage people to quit for fear ...
... percent of people, usually in middle age. People with the ... It is not the type of arthritis common in the ... the immune system goes awry and attacks the joints, causing ... stiffness. It is also linked to an increased risk of ...
... of a catastrophic conditions in organ transplant patients, Doctor's ... develop hardened arteries, a condition// called arteriosclerosis, in the ... team from the Maryland's Women's Hospital, USA, found ... during a year-long study. Dr James Fang, who led ...
... Alzheimer's is a degenerative brain disease that usually ... events or familiar tasks. The disease eventually leads// ... judgment. Communication becomes more difficult as the disease ... finish thoughts or follow directions. Eventually, most people ...
... Research suggests that anxiety during pregnancy can increase a ... indicated that women who were very anxious// in the ... behavioural problems. ,Lead researcher Professor Vivette Glover, ... to women who had extreme anxiety, and were frequently ...
... to Dr. John Poll, curing a laborious birth defect that ... sliced apart all the bones of her face but didn't ... a promising alternative to grueling bone grafts: Poll attached a ... each day with a screwdriver, slowly pulling out the sunken ...
Cached Medicine News:Health News:Surgery-Rigged pulley helps patients 2
(Date:8/28/2015)... 28, 2015  Perrigo Company plc ("Perrigo") (NYSE: ... the acquisition of leading OTC brands from GSK in ... transaction is a clear demonstration of Perrigo,s unique ability ... distribution network spanning 36 countries.  Perrigo ... commented, "We are excited to complete this transaction, which ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2
... Simulation Corporation (MSC) is proud to offer innovative, guideline-based ... through the Health Care Innovation Challenge, announced on November ... Services. Simulation provides a unique, risk-free environment ... in managing patients with diagnoses associated with high mortality ...
... International Corporation (NASDAQ: PRXL ), a leading ... been selected as one of two strategic partners by ... services worldwide. PAREXEL will work with UCB ... to increase productivity and cost effectiveness. The ...
Cached Medicine Technology:Medical Simulation Corporation Offers Innovative Training Solutions for Healthcare Organizations Applying to the Department of Health and Human Services' Health Care Innovation Challenge 2UCB and PAREXEL Sign Strategic Partnership Agreement 2UCB and PAREXEL Sign Strategic Partnership Agreement 3UCB and PAREXEL Sign Strategic Partnership Agreement 4
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
The TBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of total bilirubin in serum and plasma...
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
Medicine Products: